2009
New approaches for the assessment of vessel sizes in quantitative (cardio-)vascular X-ray analysis
Janssen JP, Rares A, Tuinenburg JC, Koning G, Lansky AJ, Reiber JH. New approaches for the assessment of vessel sizes in quantitative (cardio-)vascular X-ray analysis. The International Journal Of Cardiovascular Imaging 2009, 26: 259-271. PMID: 19888671, PMCID: PMC2846330, DOI: 10.1007/s10554-009-9526-2.Peer-Reviewed Original ResearchImpact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial)
Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW. Impact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial). The American Journal Of Cardiology 2009, 103: 1196-1203. PMID: 19406258, DOI: 10.1016/j.amjcard.2009.01.030.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAge FactorsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsCause of DeathDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyEnoxaparinFemaleFollow-Up StudiesHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProportional Hazards ModelsRecombinant ProteinsReference ValuesRisk AssessmentSeverity of Illness IndexSex FactorsSurvival AnalysisTime FactorsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsElevation acute coronary syndromePercutaneous coronary interventionAcute coronary syndromeComposite ischemiaNet clinical outcomeMajor bleedingCoronary syndromeClinical outcomesNet clinical adverse eventsIIb/IIIa inhibitorsLate clinical outcomesCoronary artery bypassClinical adverse eventsImpact of genderACUITY trialBivalirudin monotherapyAntithrombotic therapyArtery bypassNon–STAdverse eventsAntithrombotic strategiesCoronary interventionIschemiaBivalirudin
2008
The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale
Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. American Heart Journal 2008, 156: 44-56. PMID: 18585496, DOI: 10.1016/j.ahj.2008.02.008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngioplasty, Balloon, CoronaryAnticoagulantsCombined Modality TherapyCoronary AngiographyDose-Response Relationship, DrugDrug Administration ScheduleDrug-Eluting StentsFollow-Up StudiesHeparin, Low-Molecular-WeightHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProspective StudiesRecombinant ProteinsReference ValuesResearch DesignRisk AssessmentStentsSurvival RateThrombosisTime FactorsConceptsPrimary PCIPrimary percutaneous coronary interventionIIb/IIIa inhibitorsAcute myocardial infarctionBare metal stentsGP IIb/IIIa inhibitorsHORIZONS-AMI trialUnfractionated heparinGlycoprotein IIb/IIIa inhibitorsIdentical bare-metal stentOverall event-free survivalAcute Myocardial Infarction trialEnd pointDirect thrombin inhibitor bivalirudinRoutine useEfficacy end pointMyocardial Infarction trialTarget lesion revascularizationEvent-free survivalClinical end pointsPercutaneous coronary interventionPaclitaxel-eluting stentsNew pharmacologic agentsThrombin inhibitor bivalirudinDrug-eluting stents
2005
Intravascular Ultrasonic Assessment of Stent Diameters Derived from Manufacturer’s Compliance Charts
de Ribamar Costa J, Mintz GS, Carlier SG, Costa RA, Fujii K, Sano K, Kimura M, Lui J, Weisz G, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Intravascular Ultrasonic Assessment of Stent Diameters Derived from Manufacturer’s Compliance Charts. The American Journal Of Cardiology 2005, 96: 74-78. PMID: 15979438, DOI: 10.1016/j.amjcard.2005.02.049.Peer-Reviewed Original ResearchConceptsManufacturers' compliance chartsMinimum stent diameterCompliance chartsStent diameterIntravascular ultrasoundStent sizeDe novo coronary lesionsDeployment pressureNovo coronary lesionsMinimal stent diameterHuman coronary arteriesStent manufacturersCoronary lesionsIVUS guidanceCoronary arteryStent lengthInterventional cardiologistsPhysician reportsPercutaneous proceduresStent overlapDifferent stent lengthsStentsBoston ScientificUltrasonic assessmentBare metal
1998
Paradoxic Decreases in Atherosclerotic Plaque Mass in Insulin-Treated Diabetic Patients
Kornowski R, Mintz G, Lansky A, Hong M, Kent K, Pichard A, Satler L, Popma J, Bucher T, Leon M. Paradoxic Decreases in Atherosclerotic Plaque Mass in Insulin-Treated Diabetic Patients. The American Journal Of Cardiology 1998, 81: 1298-1304. PMID: 9631966, DOI: 10.1016/s0002-9149(98)00157-x.Peer-Reviewed Original ResearchConceptsArterial areaPlaque accumulationLumen compromiseDe novo native coronary stenosisInsulin-treated patientsInsulin-treated diabeticsNative coronary stenosisMultivariate linear regression analysisAtherosclerotic lesion formationBody surface areaParadoxic decreaseInsulin useDiabetes mellitusDiabetic patientsIndependent predictorsRemodeling indexAnginal syndromePlaque burdenCoronary stenosisArterial shrinkageInsulin treatmentPlaque massIntravascular ultrasoundLinear regression analysisReference segments